Repression of Wnt/β-catenin response elements by p63 (TP63)

Iyoko Katoh\textsuperscript{a,b}, Nahoko Fukunishi\textsuperscript{c,d}, Masahiro Fujimuro\textsuperscript{d}, Hirotake Kasai\textsuperscript{a}, Kohji Moriiishi\textsuperscript{a}, Ryu-Ichiro Hata\textsuperscript{b}, and Shun-ichi Kurata\textsuperscript{a,b,c}

\textsuperscript{a}Center for Medical Education and Sciences, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan; \textsuperscript{b}Oral Health Science Research Center, Kanagawa Dental University, Yokosuka, Japan; \textsuperscript{c}Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan; \textsuperscript{d}Department of Cell Biology, Kyoto Pharmaceutical University, Yamashina, Kyoto, Japan; \textsuperscript{e}Department of Microbiology, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan

ABSTRACT
Submitted: TP63 (p63), a member of the tumor suppressor TP53 (p53) gene family, is expressed in keratinocyte stem cells and well-differentiated squamous cell carcinomas to maintain cellular potential for growth and differentiation. Controversially, activation of the Wnt/β-catenin signaling by p63 (Patturajan M. et al., 2002, Cancer Cells) and inhibition of the target gene expression (Drewelus I. et al., 2010, Cell Cycle) have been reported. Upon p63 RNA-silencing in squamous cell carcinoma (SCC) lines, a few Wnt target gene expression substantially increased, while several target genes moderately decreased. Although ∆Np63α, the most abundant isoform of p63, appeared to interact with protein phosphatase PP2A, neither GSK-3β phosphorylation nor β-catenin nuclear localization was altered by the loss of p63. As reported earlier, ∆Np63α-repressed WREs mediated by p63-OT having 3 artificial Wnt response elements (WREs). However, this activation was detectable only in HEK293 cells examined so far, and involved a p53 family-related sequence 5′ to the WREs. In Wnt3-expressing SAOS-2 cells, ∆Np63α rather strongly inhibited transcription of pGL3-OT. Importantly, ∆Np63α repressed WREs isolated from the regulatory regions of MMP7. ∆Np63α-TCF4 association occurred in their soluble forms in the nucleus. Furthermore, p63 and TCF4 coexisted at a WRE of MMP7 on the chromatin, where β-catenin recruitment was attenuated. The combined results indicate that ∆Np63α serves as a repressor that regulates β-catenin-mediated gene expression.

Introduction

TP63 (p63), a TP53 (p53)-related gene, is expressed in keratinocyte stem cells to maintain the cellular potential of proliferation and keratinocyte differentiation.\textsuperscript{1-5} It is essential for morphogenesis of ectodermal tissues including skin, glands, head-and-neck, limb and urinary tracts.\textsuperscript{6,7} Mutations of this gene cause the EEC and related syndromes.\textsuperscript{8,9} Furthermore, the chromosome 3q amplification in head-and-neck squamous cell carcinomas (SCCs) underlies the high level expression of p63 (3q27-q29).\textsuperscript{10,11} This gene produces at least 6 proteins termed variant 1-6 (National Center for Biotechnology Information, USA). Due to the 2 different transcription initiation sites, the TA-isoforms (variant 1-3) with the trans-activation domain and the ΔN-isoforms (variant 4-6) without TA are produced. For each N-terminal variant, alternative RNA splicing causes 3 different C-terminal structures, α, β, and γ\textsuperscript{1}.\textsuperscript{1,2,3} TAp63γ, originally identified as p51A, has a trans-activating ability similar to p53 to act on the same consensus sequences.\textsuperscript{1,3,12} Many of the direct target genes determined for TAp63γ are involved in cell-cell and cell-matrix interactions.\textsuperscript{12-17} In contrast to the lower level expression of TAp63γ, ∆Np63α (variant 4) is the most abundant isoform detected in the basal layer stem cells, SCCs, and cancers originating from basal cells of ectoderm.\textsuperscript{13,18-21} ∆Np63α comprises DNA binding domain, oligomerization domain and sterile α motif with which various proteins can interact.\textsuperscript{22} Although initial studies experimentally identified ∆Np63α as a dominant negative-type protein against TAp63γ and p53,\textsuperscript{1} the trans-activating ability of TAp63γ seems vital in keratinocytes and SCCs. The dominant negative-type action may not be the only function of ∆Np63α.\textsuperscript{23,24}

Because invasion of SCCs coincides with a steep decline in p63 expression, maintenance of the well-differentiated status by p63 has been proposed.\textsuperscript{25,26} As well-documented for colorectal and hepatocellular carcinomas, carcinogenesis and malignant progression are often accompanied by somatic mutations resulting in Wnt signal activation.\textsuperscript{27-29} Head-and-neck SCCs, however, rarely have a mutation in the major factors such as
APC and CTNNB1 (β-catenin).\textsuperscript{10} The possibilities of positive and negative regulation of Wnt/β-catenin signaling by p63 has been proposed in earlier studies. Patturajan M. et al. reported activation of the Wnt signaling to accumulate β-catenin through protein phosphatase 2A (PP2A) inhibition by ΔNp63α.\textsuperscript{30} On the other hand, Drewelus I. et al. proposed that p63 blocks β-catenin-induced transcription.\textsuperscript{31} The authors detected a specific interaction between ΔNp63α and the HMG box of TCF1, TCF3, TCF4, and LEF1 by a pulldown assay.

Confusingly, however, these reports concurred in one point that ΔNp63α enhances luc gene expression from the prototype reporter plasmids in HEK293 cells. TOPflash (referred to as LeF1: luciferase reporter plasmid by Patturajan et al.\textsuperscript{30}) and that D box of TCF1, TCF3, TCF4, and LEF1 by a pulldown assay.

Expression of p63 is deeply investigated in the inactivation with the above described con mechanism impairing the ambiguity caused by the reporter assay, our results further support the notion that p63 is specifically expressed in the basal layer of keratinocytes and well-differentiated SCCs. Our gene expression profiling of SCC lines showed substantial alterations in target genes of p53 and p63, and basal layer keratinocyte-specific genes by p63 knockdown. It was of interest that some Wnt target genes were activated by p63-silencing, while some others were down-regulated. These results, in conjunction with the above described conflicting reports, led us to deeply investigate the influence of p63 over the Wnt/β-catenin signaling pathway and the target gene expression. We reexamined the reporter gene expression assay, and the signaling proteins in the cytosol and nucleus. Furthermore, we tested endogenous WRE sequences upstream of the Wnt/β-catenin target genes for their sensitivity to β-catenin and p63. Eliminating the ambiguity caused by the reporter assay, our results strongly suggest that β-catenin-mediated gene expression is impaired by ΔNp63α in SCCs. This study provides new evidence for the prediction by Drewelus I. et al.,\textsuperscript{31} and offers deeper insights into the function of p63.

\section*{Results}

\subsection*{Alteration of Wnt target gene expression by p63 RNA silencing}

FaDu cells are derived from a hypopharyngeal carcinoma, and expresses ΔNp63α with other p63 isoforms.\textsuperscript{25,30} Based on the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Sanger Institute, UK), this cell line has a missense mutation (c.743G>T, p.R248L) in \textit{CDKN2A} and an intronic mutation (c.151-1G>T) in \textit{CDKN2A} (cyclin-dependent kinase inhibitor 2A, also termed p14ARF/p16INK4a). No mutation related to the canonical Wnt signaling has been identified in these cells so far.

We performed gene expression profiling with FaDu cells transfected with p63-specific siRNA (p63si) and control siRNA (Csi). p63 RNA was decreased to 1/4 – 1/6.5 in p63si-transfected cells compared with Csi-transfected cells, indicating efficient RNA silencing (Table 1). NOTCH, JAG2, COL7A1, and DST among the reported p63-target genes,\textsuperscript{33} were obviously downregulated by p63 silencing in varied magnitudes. Concerning the TP53 target genes,\textsuperscript{34} suppression of GADD45A and BAX\textsuperscript{35} and activation of p53IP1\textsuperscript{36} and p53IP2\textsuperscript{37} were evident in p63 knockout cells, implying involvement of the trans-activating and dominant-negative functions of the p63 isoforms. Furthermore, expression of the basal cytokeratin genes, KER14 (K5), decreased with p63-silencing, consistent with the notion that p63 is specifically expressed in the basal layer of keratinocytes and well-differentiated SCCs. Of interest was that some of the Wnt target genes, AXIN2 (K14), and KER5 (K5), decreased with p63-silencing, consistent with the notion that p63 is specifically expressed in the basal layer of keratinocytes and well-differentiated SCCs. Of interest was that some of the Wnt target genes, AXIN2 (K14), and KER5 (K5), decreased with p63-silencing, consistent with the notion that p63 is specifically expressed in the basal layer of keratinocytes and well-differentiated SCCs. Of interest was that some of the Wnt target genes, AXIN2 (K14), and KER5 (K5), decreased with p63-silencing, consistent with the notion that p63 is specifically expressed in the basal layer of keratinocytes and well-differentiated SCCs.

We confirmed these changes in the Wnt target gene expression by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blotting (Fig. 1). p63 proteins decreased to less than 15% in p63si-transfected cells, while total p63 RNA decreased to 40% when quantified with our primers. RNA of FaDu cells.

\begin{table}[h]
\centering
\caption{Alteration of gene expression by p63 silencing in squamous carcinoma FaDu cells.}
\begin{tabular}{llll}
\hline
Experiment & 1 & 2 & 3 \\
\hline
p63 & & & \\
TP53 & -6.519 & -3.904 & -4.355 \\
Reported p63 target genes & & & \\
\textit{NOTCH1}\textsuperscript{**} & -3.187 & -1.609 & -1.967 \\
\textit{JAG2}\textsuperscript{**} & -3.339 & -1.583 & -1.654 \\
\textit{COL7A1}\textsuperscript{**} & -2.826 & -3.068 & -2.954 \\
\textit{JAG1}\textsuperscript{**} & -2.812 & -1.678 & -1.565 \\
\textit{CLDN1}\textsuperscript{**} & -2.082 & -1.048 & -1.207 \\
\textit{DST}\textsuperscript{**} & -1.339 & -3.071 & -3.391 \\
p53 target genes & & & \\
\textit{GADD45A} & -6.761 & -3.333 & -2.083 \\
\textit{BAX} & -5.534 & -1.176 & -1.078 \\
\textit{TP53IP1} & ND & +3.518 & +3.978 \\
\textit{TP53IP2} & ND & +2.780 & +1.180 \\
Keratinocyte-specific genes & & & \\
\textit{LCES5} & -6.338 & +1.502 & -1.819 \\
\textit{KRT5} (basal) & -3.250 & -2.849 & -2.849 \\
\textit{KRT17} (basal) & -3.382 & -2.108 & -2.108 \\
\textit{KRT16} & -3.496 & -1.083 & -1.083 \\
\textit{KRT14}\textsuperscript{**} (basal) & -3.030 & -2.240 & -2.240 \\
Wnt target genes & & & \\
\textit{AXIN2} & +14.411 & +7.302 & +4.311 \\
\textit{MMP7} & +5.469 & +7.221 & +5.989 \\
\textit{MIF} & +4.432 & +2.681 & +2.914 \\
\textit{DKK1} & ND & +2.190 & +2.753 \\
\textit{SNAI2} (SLUG) & -5.877 & -3.323 & -3.045 \\
\textit{CCND2} & -3.489 & -2.353 & -2.391 \\
\textit{LBH} & -3.415 & -1.822 & +1.039 \\
\textit{NEGFA} & -3.087 & -2.897 & -2.426 \\
\textit{JAG1}\textsuperscript{**} & -2.812 & -1.678 & -1.565 \\
\textit{MYC} & -2.628 & -1.760 & -2.228 \\
\textit{CLDN1} & -2.082 & -1.048 & -1.207 \\
\textit{TWIST1} & -1.243 & -1.327 & -4.047 \\
\textit{EDN3} & -1.746 & -2.188 & -1.900 \\
\hline
\end{tabular}
\end{table}

\textsuperscript{*}Upregulation (+) and downregulation (-) are indicated. \textsuperscript{**}reported p63 target gene. ND, not determined.

\begin{itemize}
\item 3\textsuperscript{rd} fold increase in the \textit{MMP}-protein and 2.5-fold decrease in the \textit{CCND2} protein (Fig. 1B).
\end{itemize}
Interaction of ΔNp63α with PP2A phosphatase

We next analyzed proteins in the Wnt/β-catenin signaling pathway focusing on GSK-3β and β-catenin phosphorylation by cell fractionation and immunoprecipitation (Fig. 2). The FaDu cell cytosol fractions were enriched in the PP2A catalytic subunit (PP2A-C), while the nuclear fractions showed localization of the PP2A B56α (PPP2R5A) regulatory subunit (Fig. 2A). An antibody against PP2A-C (clone ID6) precipitated not only PP2A-C but also PP2A-B56α. As reported earlier,43 ΔNp63α existed in the PP2A-C immune complex from the control (Csi) nucleus, but not from the p63 knockdown nucleus (p63si) (Fig. 2A). After PP2A-C gene (PPP2CA, PPP2CB) silencing with siRNA (PPsi), immunoprecipitation was carried out with the PP2A-C antibody (Fig. 2B). When the PP2A-C protein amount decreased to ~25% in the immunoprecipitate (IP, PPsi) as well as in the nuclear fraction (input, PPsi), the amount of co-precipitated ΔNp63α decreased concomitantly.

We performed a PP2A phosphatase assay in which the release of phosphate from a phospho-threonine peptide substrate was quantified. The PP2A activity in the whole-cell extracts did not substantially change with p63-silencing (Fig. 2C). GSK-3β (a substrate of PP2A) and β-catenin (a substrate of GSK-3β) showed no significant alteration in the protein amount, phosphorylation or subcellular localization (Fig. 2A, lower panels). Immunofluorescence analysis showed dense stain of β-catenin at the cell periphery and its spread throughout the cytosol. The nuclei were stained only weakly. No significant difference appeared between the p63-knockdown and control cells regarding β-catenin fluorescence intensity and distribution (Supplementary Information-1).

Association of ΔNp63α with TCF4

To further analyze protein interactions between Wnt signaling proteins and p63, we introduced flag-tagged β-catenin in combination with ΔNp63α or the empty expression vector into HeLa cells. Flag-β-catenin was immunoprecipitated with an anti-flag antibody from the cytosol and nuclear extracts (Fig. 2D). Fractionation efficiency was assessed with HSP90 and p84, representing the cytosol and nuclear proteins, respectively. The flag-β-catenin immune complex did not contain endogenous TCF4 observed as a triplet including a major band of 75 kD, corresponding to the longest
form of the splicing variants, nor was ΔNp63α associated with flag-β-catenin. Furthermore, ΔNp63α did not influence β-catenin nuclear translocation. In addition, PP2A-C and PP2A-B56α interacted with Flag-β-catenin only poorly, if at all.

When Myc-tagged TCF4 expression plasmid was co-transfected with ΔNp63α or the vector plasmid, immunoprecipitation with an anti-Myc antibody revealed a strong association of Myc-TCF4 with ΔNp63α in the nucleus (Fig. 2E). PP2A-B56α and PP2A-C were poorly detectable in the precipitates...
regardless of ΔNp63α. Furthermore, we did not find p53 or Flag-β-catenin by the anti-myc immunoprecipitation. As a control experiment, Myc-tagged β-catenin expression plasmid was cotransfected with ΔNp63α (Fig. 2E, right panels). The anti-Myc antibody efficiently precipitated Myc-β-catenin, but not ΔNp63α. We thus confirmed the specific interaction between ΔNp63α and TCF4.31

luc reporter assay with pGL3-OT

To assess the influence of p63 on the β-catenin-mediated gene expression, a luc gene reporter assay was performed with pGL3-OT, pGL3-OF and the truncated forms (Fig. 3A-C). Consistent with the previous reports, ΔNp63α dose-dependently enhanced luc expression from pGL3-OT only when activated by β-catenin in HEK293 cells (Fig. 3D). Cotransfection of TCF4 (25 ng of the plasmid in each well) neither positively nor negatively influenced the response to β-catenin (25 ng) with p63 (0-50 ng) (Supplementary Information 2A). Among the p63 isoforms transfected, ΔNp63α exhibited the strongest β-catenin-enhancing ability with pGL3-OT (Supplementary Information-2B). When the maximum transcriptional activation (50-fold) was achieved with a S33Y β-catenin mutant (20-50 ng/10⁵ cells), ΔNp63α could not further increase the luc expression (Supplementary Information-2C). pGL3-OF which has 2 nucleotide mutations in each WRE did not respond to β-catenin or ΔNp63α (Fig. 3E).

Intriguingly, we found a repeat of 10 nucleotide sequences corresponding to the originally proposed half site of p53 binding motif 44 immediately 5’ to the WREs. We tentatively termed
it p53FM (p53 family protein binding motif), because it was recognizable by p63 proteins. Deletion of p53FM from pGL3-OT preserved its sensitivity to β-catenin, but canceled the transcriptional activation by ΔNp63α (Fig. 3F). The p53FM sequence per se showed neither positive nor negative response to ΔNp63α (Fig. 3G).

SAOS-2 is a p53-null osteosarcoma cell line, by which functions of p53 family proteins are sensitively monitored (Supplementary Information-3A). In addition, these cells constantly express a higher level of Wnt3a, β-catenin and LEF1, which maintain the cellular signaling and growth potential. In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.

In hepatocellular carcinoma Huh7 cells, luc expression from pGL3-OT was also decreased by ΔNp63α in the persistent and encoded plasmid, respectively, in each well (Fig. 4A). TCF4-expression plasmid (25 ng in each reaction) was contained in every reaction with SAOS-2 cells, by which the level of transcriptional activation by β-catenin (50 ng) was 3-fold elevated. (Compare panel A with Supplementary Information-3B.) pGL3-OT-del-p53FM responded to β-catenin at nearly the same sensitivity (Fig. 4B). Unexpectedly, ΔNp63α strongly inhibited luc expression from pGL3-OT and pGL3-OT-del-p53FM when induced by β-catenin transfection in SAOS-2 cells. ΔNp63α also decreased the basal level transcription from these luc plasmids without β-catenin transfection.
β-catenin-induced conditions (Fig. 4D). Furthermore, p63-silencing in FaDu cells caused a 2.8-fold increase in the luciferase activity (Fig. 4C). Thus, these results obtained with pGL3-OT in SAOS-2, Huh7 and FaDu cells were consistent with the result that endogenous MMP7 and AXIN2 were activated by p63-silencing (Table 1, Fig. 1).

Repression of chromosomal WREs by p63

To explore the transcriptional control of Wnt target gene by ΔNp63α, we analyzed endogenous WREs for their activities and regulation. Using the proposed consensus sequences, we detected several WREs in the 10 kb regulatory regions of MMP7 and CCND2, and cloned 3 segments containing repetitive WREs into a reporter plasmid (pGL3-promoter vector). The MMP7-WRE1 segment located 5.6 kb upstream from the initiation site had a pair of WRE core sequences, 5′-YCTTTGAT-3′, with one nucleotide mismatch in the second WRE (Fig. 5A). The region containing the known WREs at −194 and −109 (reference 40) was referred to as MMP7-WRE2 in this study (Fig. 5B). At 2.2 kb upstream of CCND2, we identified an interesting segment termed CCND2-WREb, which comprised a
palindromic WRE repeat preceded by 3 half-sites (10 nucleotides) of p53 binding consensus (Fig. 5C). We also constructed MMP7-WRE1-rep-luc and CCND2-WREb-rep-luc by inserting an additional copy of the corresponding WRE pair.

In SAOS-2 cells, both MMP7-WRE1-luc and MMP7-WRE2-luc caused only a 1.5-1.8-fold increase when co-transfected with the β-catenin expression plasmid (67 ng in each well) (Fig. 5D, F). This moderate activation was canceled by ΔNp63α. The basal level transcription was also affected. The MMP7-WRE1-rep-luc and CCND2-WREb-rep-luc plasmids showed 2-fold and 3-4-fold activation by cotransfection with 50 and 67 ng of the β-catenin plasmid, respectively (Fig. 5E, G). ΔNp63α suppressed the luc expression from these plasmids in a dose-related manner.

Huh7 with an endogenous Wnt signaling activity caused only 2-fold activation of MMP7-WRE1-rep-luc when transfected with β-catenin (67 ng). ΔNp63α decreased the luciferase activity in the persistent and β-catenin-transfected conditions (Fig. 4E). In HEK293, luc expression from MMP7-WRE1-luc was slightly (20%) increased by β-catenin, which was inhibited by ΔNp63α. Only a 50% increase was found with CCND2-WREb-rep-luc upon induction by active form S33Y β-catenin, which was also blocked by ΔNp63α (data not shown). Thus, ΔNp63α repressed the endogenous WREs in SAOS-2, Huh7 and HEK293 cells. The sequences related to p53 half-sites in CCND-WREb did not act like p53FM that allowed positive regulation of WREs by ΔNp63α in HEK293.

**Association of p63 with MMP7-WRE1 on the chromatin**

Chromatin immunoprecipitation was carried out with Csi and p63si-transfected FaDu cells. Sheared chromatin containing 200-800 bp DNA fragments were immunoprecipitated with anti-p63, anti-TCF4, anti-β-catenin and control IgG. Recovered DNA fragments were quantified by qPCR with primers targeting MMP7-WRE1 and CCND2-WREb (Fig. 6). Both p63 and TCF4 were detected at the MMP7-WRE1 site in Csi-transfected cells (Fig. 6A). By p63 RNA silencing, p63 protein at MMP7-WRE1 was significantly decreased, which was accompanied by an approximately 2.5-fold increase of β-catenin protein bound to the site. Thus, p63 coexisted with TCF4 at MMP7-WRE1, by which recruitment of β-catenin was impaired. However, none of the immunoprecipitates from Csi or p63si-transfected cells contained the CCND2-WREb segment, suggesting that this site on the chromatin does not function as a Wnt/β-catenin target site in FaDu cells (Fig. 6B).

**Discussion**

This study strongly suggests that p63 serves as a repressor of WREs to attenuate Wnt/β-catenin target gene expression. Gene expression profiling of p63 knockdown cells implied negative regulation of Wnt/β-catenin target genes by p63. ΔNp63α suppressed luc expression driven by cloned endogenous WREs with β-catenin. Furthermore, p63-TCF4 association in the nuclear extract, coexistence of p63 with TCF4 at a chromosomal WRE site, and interference of β-catenin binding to the target site by p63 may explain the mechanism of transcriptional downregulation.

As used in many studies, pGL3-OT in combination of HEK293 cells provides a standard reporter assay for analyses of Wnt/β-catenin signaling pathway activation. With this system, however, we observed the opposite outcome regarding the p63 function. At least p53FM in the plasmid seemed to contribute...
to the reaction. TOPflash and SuperTOPflash, the earlier versions of pGL3-OT, also have sequences related to p53FM at a position close to the WRE repeats, which may have caused the contradiction in previous studies. Drewelus et al. hypothesized a switching mechanism between the positive and negative regulation depending on the p63 concentration. However, we failed to detect it in the luc assays with different amounts of the ΔNp63α expression plasmid.

HEK293 cells were transformed by adenovirus type-5 E1A and E1B genes and constitutively express them. The small E1A oncoprotein interacts with Rb, p300/CBP, etc. to cause genome-wide transcriptional and epigenetic changes, while E1B 55 k0 protein binds p53 to block the function. These viral proteins potentially influence p63 and nuclear factors of the Wnt signaling pathway. Hypothetically, the (p53FM)-(WREs) structure of pGL3-OT might allow ΔNp63α, TCF and β-catenin to form an activating complex under the influence of E1A and/or E1B. However, there has been so far no evidence for a chromosomal gene controlled by the (p53FM)-(WREs)-type enhancer. Intriguingly, the twin gene of Xenopus laevis has a tandem arrangement of (Smad binding sites)-(Lef1/Tcf binding sites), which is activated synergistically by Smad, Lef1 and β-catenin.

Wnt3a-expressing p53-null SAOS-2 cells provided a sensitive assay system for β-catenin-driven luc expression. ΔNp63α evidently repressed luc expression from pGL3-OT. Importantly, the WRE repeats cloned from the MMP7 and CCND2 regulatory regions also positively responded to β-catenin albeit weakly (4-fold at most), and were repressed by ΔNp63α. Experiments with Huh7 and FaDu cells supported this result. In addition to the previously identified WREs at −109 and −194 (collectively termed WRE2 in this study) of MMP7, WRE1 at −5.4 kb was also able to mediate β-catenin-induced transcriptional activation.

In the previously proposed model, formation of a quadruple protein complex of p63, TCF/LEF, β-catenin and unidentified repressor molecule was hypothesized. Our ChIP experiment suggests that interaction of p63 with TCF4 bound to MMP7-WRE1 reduces the accessibility of β-catenin to TCF4. Although the antibody against p63 does not discriminate p63 isoforms, ΔNp63α most likely represents the precipitated p63 isoforms based on its abundance and ability to form a complex with TCF4 as detected by immunoprecipitation (Fig. 2D). It remains to be investigated whether or not ΔNp63α requires corepressor Groucho/TLE1 for the control of β-catenin.

Among the TCF/LEF family proteins, we focused on TCF4. Tcf3 and Tcf4 are expressed in keratinocyte stem cells, and play essential roles for skin homeostasis in mice. Furthermore, TCF4 binding sequences were extensively studied in colon cancer cells and found to match the proposed WREs.

The Wnt/β-catenin target genes moderately downregulated in p63 knockdown cells, including CCND2 and JAG1, may not be governed by the Wnt signaling pathway in FaDu. Whereas CCND2-WREβ responded to β-catenin in the reporter assay, TCF4, p63 and β-catenin were missing at the site on the chromosome of FaDu. JAG1 is not only a Wnt target gene but also a p63 target gene. The interaction between ΔNp63α and PP2A B56α found in the previous study might be functional in some way, apart from the Wnt signaling. Ruptier et al. reported that the ΔNp63 promoter is activated by β-catenin in human hepatocellular carcinomas. In fact, HepG2 and Huh7 cells express ΔNp63 isoforms poorly in comparison with SCC lines. In some cellular contexts, ΔNp63α might play a negative feedback function to limit the ΔNp63 transcription.

MMP7 was identified as a target gene of TCF-4/β-catenin, being overexpressed in colorectal cancers with Wnt signaling pathway activation. Matrix metalloproteinase-7 catalyzes breakdown of extracellular matrix proteins, and is frequently expressed in the phase of invasion and metastasis of gastric and renal carcinomas. In SCCs, its transcriptional suppression may be abolished by the loss of p63 with the malignant conversion. Although Axin2 was originally found as a negative regulator of Wnt/β-catenin signaling, a recent study observed a tumor promoting activity of the protein in colorectal cancers. Thus, the WRE-repressing function of p63 provides an explanation for the generally accepted notion that SCCs gain a malignant phenotype when p63 is diminished.

Materials and methods

Cell lines

FaDu (HTB-43) and SAOS-2 (HTB-85) were from American Type Culture Collection. HEK293 (JCRB9068), HeLa (JCRB9004) and Huh7 (JCRB0403) were from Japanese Collection of Research Bioresources.

RNA interference

siRNA transfection was described. Anti-p63 siRNA (p63si) consisted of IMXRu (sense RNA, 5’-gagacgauaaccaggacttt-3’; antisense RNA, 5’-agucagguagcaagctc3’), and CUBCP (sense RNA, 5’-gacgauaaccaggacttt-3’; antisense RNA, 5’-agucagguagcaagctc3’). Control siRNA Csi (AM4636, Ambion) was from (Thermo Fisher Scientific). Stealth siRNA (HS0108360, HSS108361) targeting PP2A-C genes (PP2CA, PP2PCB) were from Invitrogen (Thermo Fisher Scientific).

Gene expression profiling

RNA was obtained from cells transfected with Csi and p63si, and clarified with RNasy MinElute Cleanup Kit (Qiagen). DNA microarray analysis was performed by Oncomics with the system from Agilent technologies including Quick Amp labeling kit, 2-color (5190-0444), Agilent RNA Spike-In kit, 2-color (5188-5279), Whole Human Genome Microarray kit (version 2.0), Gene Expression Hybridization kit (5188-5242) and GeneSpring GX software (version12.5.0).

qRT-PCR

RNA was purified with High Pure RNA Isolation kit (Roche). Random primed reverse transcription was with RevertAid Reverse Transcriptase (Thermo Fisher Scientific). PCR was performed with DyNAmo ColorFlash SYBR Green qPCR kit in the PikoReal Real-Time PCR System (Thermo Fisher Scientific). Primers were: hGAPDH-F2 (5’-aacaattgtgtctggaagc-3’), hGAPDH-R2 (5’-ggcatcacgcaagcgt-3’), p63ALL-F (5’-cctcacacggactacctc-3’),
p63ALL-R (5'-caccgctcaccacctcgt-3'), MMP7-F2 (5'-gagtgcagtagtgggaaca-3'), MMP7-R2 (5'-catgacagggaggttaacta-3'), AXIN2-F1 (5'-caacccagggccaagaa-3'), AXIN2-R1 (5'-gccaataagggtgtagggt-3'), CCND2-F (5'-acccctcgagttctctca-3'), CCND2-R (5'-caccgcaaaacagtgctc-3'), SNAI2-F2 (5'-cgaatgacaccatacaggg-3'), SNAI2-R2 (5'-ctgagacctctggtgtggt-3') and c-Myc-F (5'-aagggcccagatctc-3') and c-Myc-R (5'-aaaggc cccaaagtagatg-3').

**Antibodies used for immunoprecipitation and Western blotting**

A PP2A-C subunit antibody (clone ID6, 05-421) and a TCF4 antibody (05-511) were from Merck Millipore. A PPR2R5A (B560) antibody (Ab72028), a nuclear protein p83 antibody (Ab487) and a Myc tag antibody (ab9106) were from Abcam. Cell Signaling Technology supplied antibodies against GSK-3β (#9315), phospho-GSK-3β (Ser9) (#9323), C-terminal β-catenin (#9587), phospho-β-Catenin (Ser33/37) (#2009) and DYKDDDDK (#8146). Also supplied were alkaline phosphatase-conjugated secondary antibodies against mouse IgG (#7056) and rabbit IgG (#7054). Santa Cruz Biotechnology (Dallas, TX) supplied anti-MMP7 (sc-80205), anti-Cyclin D2 (sc-181) and anti-p53 (Pab1801, sc-98) antibodies. An anti-p63 monoclonal antibody (4A4) was from Santa Cruz Biotechnology (sc-8431) and also from Abcam (Ab735). An anti-DDDK monoclonal antibody (4A4) was from Santa Cruz Biotechnology.

**PP2A enzyme assay**

PP2A Immunoprecipitation Phosphatase Assay Kit (Millipore) was used for immunoprecipitation and enzyme activity quantification. One reaction contained 500 ng of sonicated cell lysate (aliquot corresponding to 2.5 × 10⁵ cells). Released phosphate amounts were measured by a malachite green colorimetric assay. Experiments were performed 4 times with 2 technical replicates.

**Plasmids**

pGL3-OT, pGL3-OF, wild-type β-catenin cloned in pCIneo, S33Y β-catenin cloned in pCIneo, Flag-tagged β-catenin cloned in pSG5 (MF66), and Myc-TCF4 cloned in pcDNA were described. CMV promoter-driven p63 expression plasmids were described. Deletion mutants, del-p53FM and del-WREx3 were constructed by MluI-PstI and PstI-BglII digestion, respectively, followed by ligation with synthetic nucleotides minimizing the sequences to be deleted. The MMP7-WRE1 sequences were obtained from genomic DNA by PCR with primers MluI-MMP7-WRE1-F1 (5'-ctactcggtagaagagacactgtc-3') and BglII-MMP7-WRE1-R1 (5'-gaagatcactgccaatccaaggtc-3'), and inserted at the MluI-BglII sites of the pG5-promoter vector (Promega, Madison, WI). The CCND2-WREb sequences were ampliﬁed with primers MluI-CCND2-WREb-F1 (5'-cctcgcctgcctcggagaaggct-3') and BglII-CCND2-WREb-R1 (5'-gaagatcactgtgctcggagaaggct-3') to be inserted at the same sites. The region covering MMP7-WRE2, TATA box and initiation site was ampliﬁed with MMP7-Amp-F3 (5'-cttactcggtaatagtagcagacagacgaa-3') and MMP7-Amp-R3 (5'-cgcagatcgtggttaatctgagtt-3'), and inserted at the MluI-BglII site of pGL3-OT after excising the p53FM-WREx3-promoter region.

**Luciferase reporter assay**

Plasmids were transfected with Effectene transfection reagent (Qiagen). Cells were plated in 24-well plates at 5 × 10⁴–10⁵ cells/well 24 hr before transfection. At 48 hr of transfection cells were harvested. Luciferase assay was performed with the luciferase assay systems and Steady-Glo luciferase assay system in combination with Glo lysis buffer (Promega). The enzyme activity was quantified with Lumat LB9507 (Perkin Elmer.). Experiments were performed in 2 biological replicates with 3 technical replicates.

**Chromatin Immunoprecipitation (ChIP)**

We used the ChIP-IT High Sensitivity kit (Active Motif, Carlsbad, CA). ChIP-validated antibodies for p63 (39739, Active Motif), TCF4 (17-10109, Millipore) and β-catenin (9587, Cell Signaling Technology) were applied. Pretreated ChIP IgG (4 µg) and sheared chromatin (10 µg) were incubated overnight at 4°C, combined with washed protein G-agarose beads, and incubated for additional 3 hr. Purified DNA was quantiﬁed by qPCR with primers: MMP7-WRE1-F1 (5'-aaccggccgctgaa-gaaggct-3'), MMP7-WRE1-R1 (5'-actgcaaaacagtgctc-3'), CCND2-WREb-F2 (5'-tgcgtgctggtgaaggct-3') and CCND2-WREb-R2 (5'-tggagctcaccacccgataa-3').

**Abbreviations**

SCC squamous cell carcinoma  
WRE Wnt response element  
PP2A protein phosphatase 2A  
ChIP chromatin immunoprecipitation

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Funding**

This study was supported by Japan Society for Promotion of Sciences (JSPS) in Grant Numbers 24592827, 15K11090 (to SK) and 25460475 (to IK).

**References**

[1] Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2:305-16; PMID:9774969; http://dx.doi.org/10.1016/S1097-2765(00)80275-0

[2] Pellegreni G, Dellambra E, Golisano O, Martinelli E, Fantozzi I, Bonzanini S, Ponzi D, McKeon F, De Luca M. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci U S A 2001; 98:3156-61; PMID:11248048; http://dx.doi.org/10.1073/pnas.061032098
[3] Osada M, Ohba M, Kawahara C, Ishioka C, Kanamaru R, Katoh I, Ikawa Y, Nimura Y, Nakagawara A, Obinata M, et al. Cloning and functional analysis of human p53, which structurally and functionally resembles p53. Nat Med 1998; 4:839-43; PMID:9662378; http://dx.doi.org/10.1038/nm0798-839

[4] Senou M, Pinto F, Crum CP, McKeon F. p63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia. Cell 2007; 129:523-36; PMID:17482546; http://dx.doi.org/10.1016/j.cell.2007.02.045

[5] Keyes WM, Pecoraro M, Aranda V, Vernesson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Miruhina TV, Enikolopov G, et al. ΔNp63α is an oncogene that targets chromatin remodeler Ich to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011; 8:164-76; PMID:21295273; http://dx.doi.org/10.1016/j.stem.2010.12.009

[6] Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Crum C, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8; PMID:10227294; http://dx.doi.org/10.1038/19539

[7] Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13; PMID:10227293; http://dx.doi.org/10.1038/19531

[8] Celli J, Djuif P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newell J, Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Seno M, Pinto F, Crum CP, McKeon FD. p63Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia. Cell 2007; 129:523-36; PMID:17482546; http://dx.doi.org/10.1016/j.cell.2007.02.045

[9] Brunner HG, Hamel BC, Van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39:377-81; PMID:12070241; http://dx.doi.org/10.1136/jmg.39.6.377

[10] Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576-82; PMID:25631445; http://dx.doi.org/10.1038/nature14129

[11] Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Seno M, Pinto F, Crum CP, McKeon FD. AIS is an oncogene ampliﬁed in squamous cell carcinoma. PNAS 2000; 97:5462-7; PMID:10805802; http://dx.doi.org/10.1073/pnas.97.10.5462

[12] Sathyamurthy A, Freund SMV, Johnson CM, Allen MD, Bycroft M. Transcriptional programs regulated by p63 in normal epithelia and other syndromes. J Med Genet 2002; 39:377-81; PMID:12070241; http://dx.doi.org/10.1136/jmg.39.6.377

[13] Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 Leads to Increased Cell Migration and Up-regulation of Genes Involved in Invasion and Metastasis. Cancer Res 2006; 66:7589-97; PMID:16885380; http://dx.doi.org/10.1158/0008-5472.CAN-06-2020

[14] Segditsas S, Tomlison I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25:5731-7; PMID:17143297; http://dx.doi.org/10.1038/sj. onc.1210059

[15] Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, et al. Whole-genome sequencing identiﬁes recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23:1422-33; PMID:23788652; http://dx.doi.org/10.1101/ gr.154492.113

[16] Yang C-H, McCormick F, Levine A. Combinatorial patterns of DNA binding domain converts T-cell factors into strong Wnt effectors. Cancer Cell 2007; 6:246-54; PMID:17297308; http://dx.doi.org/10.4161/cc.6.3.3801

[17] Dreyerius I, Gopfert C, Hippel C, Dickmanns A, Damianitsch K, Pieler T, Dobbelstein M. p63 antagonizes Wnt-induced transcription. Cell Cycle (Georgetown, Tex) 2010; 9:580-87; PMID:20107313; http://dx.doi.org/10.4161/cc.9.3.10593

[18] Atcha FA, Syed A, Wu B, Hoberter NP, Yokoyama NN, Ting JH, Munguia JE, Mangalam HJ, Marsh JL, Waterman ML. A unique DNA binding domain converts T-cell factors into strong Wnt effectors. Mol Cell 2007; 27:8352-63; PMID:17893322; http://dx.doi.org/10.1128/MCB.02132-06

[19] Perez CA, Pietenpol JA. Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle (Georgetown, Tex) 2007; 6:246-54; PMID:17297308; http://dx.doi.org/10.4161/cc.6.3.3801

[20] Riley T, Sontag E, Chen P, Levine A. Transcriptional control of head and neck squamous cell carcinomas. Nature 1999; 398:708-13; PMID:10227293; http://dx.doi.org/10.1038/19539

[21] Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Seno M, Pinto F, Crum CP, McKeon FD. AIS is an oncogene amplified in squamous cell carcinoma. PNAS 2000; 97:5462-7; PMID:10805802; http://dx.doi.org/10.1073/pnas.97.10.5462

[22] Sathyamurthy A, Freund SMV, Johnson CM, Allen MD, Bycroft M. Transcriptional programs regulated by p63 in normal epithelia and other syndromes. J Med Genet 2002; 39:377-81; PMID:12070241; http://dx.doi.org/10.1136/jmg.39.6.377

[23] Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 Leads to Increased Cell Migration and Up-regulation of Genes Involved in Invasion and Metastasis. Cancer Res 2006; 66:7589-97; PMID:16885380; http://dx.doi.org/10.1158/0008-5472.CAN-06-2020

[24] Segditsas S, Tomlison I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25:5731-7; PMID:17143297; http://dx.doi.org/10.1038/sj. onc.1210059

[25] Kan Z, Zheng H, Liu X, Li S, Barber TD, Gong Z, Gao H, Hao K, Willard MD, Xu J, et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res 2013; 23:1422-33; PMID:23788652; http://dx.doi.org/10.1101/ gr.154492.113

[26] Yang C-H, McCormick F, Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J 2008; 22:2605-22; PMID:18434431; http://dx.doi.org/10.1096/fj.08-108985

[27] Perez CA, Pietenpol JA. Transcriptional programs regulated by p63 in normal epithelium and tumors. Cell Cycle (Georgetown, Tex) 2007; 6:246-54; PMID:17297308; http://dx.doi.org/10.4161/cc.6.3.3801

[28] Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9:402-12; PMID:18431400; http://dx.doi.org/10.1038/nrm2393
Nowak J, Archange C, Tardivel-Lacombe J, Pontarotti P, Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T, Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Udono T, Lim X, Tan SH, Koh WLC, Chau RMW, Yan KS, Kuo CJ, van Amerongen R, Zhou Y, Zhang E, Berggreen C, Jing X, Osmark P, Lang S, Cilio CM, Bian J, Sun Y. p53CP, a putative p53 competing protein that speciﬁcally binds to the consensus p53 DNA binding sites: A third member of the p53 family? Proc Nat Acad Sci 1997; 94:14753-8; http://dx.doi.org/10.1073/pnas.94.26.14753

Zhou Y, Zhang E, Berggreen C, Jing X, Osmark P, Lang S, Cilio CM, Göransson O, Group L, Renström E, et al. Survival of pancreatic beta cells is partly controlled by a TCF7L2-p53-p53INP1-dependent pathway. Hum Mole Gen 2012; 21:196-207; PMID:21965303; http://dx.doi.org/10.1039/hmmr/drr454

Nowak J, Archange C, Tardivel-Lacombe J, Pontarotti P, Pébuesque M-J, Vaccaro MI, Velasco G, Dagorn J-C, Iovanna JL. The TP53INP2 protein is required for autophagy in mammalian cells. Mol Biol Cell 2009; 20:870-81; PMID:19056683; http://dx.doi.org/10.1091/mbc.E08-07-0671

Lim X, Tan SH, Koh WLC, Chau RMW, Yan KS, Kuo CJ, van Amerongen R, Klein AM, Nusse R. Interfollicular Epidermal Stem Cells Self-Renew via Autocrine Wnt Signaling. Science 2013; 342:1226-30; PMID:24311688; http://dx.doi.org/10.1126/science.1239730

Takeda K, Yasumoto K, Takada R, Takada S, Watanabe K, Udono T, Saito H, Takahashi K, Shibahara S. Induction of melanocyte-specific matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999; 155:1033-8; PMID:10514384; http://dx.doi.org/10.1016/S0002-9440(99)60204-2

Huang W, Chang HY, Fei T, Wu H, Chen YG. GSK3 ß mediates ß-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79; PMID:11814047; http://dx.doi.org/10.1016/S1535-5153(01)00175-7

Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. ß-Catenin Regulates the Expression of the Matrix Metalloproteinase-7 in Human Colorectal Cancer. Am J Pathol 1999; 155:1033-8; PMID:10514384; http://dx.doi.org/10.1016/S0002-9440(99)60204-2

Lambertini E, Franceschetti T, Torreggiani E, Penolazzi L, Pastore A, Pelucchi S, Gambari R, Piva R. SLUG: a new target of lymphoid enhancer factor-1 in human osteoblasts. BMC Mol Biol 2010; 11:13; PMID:20128911; http://dx.doi.org/10.1186/1471-2199-11-13

Miyata Y, Iwata T, Okabe M, Nakajima T, Yasuda K, Shigesada N. Overexpression of matrix metalloproteins is associated with lymph node metastasis in colorectal cancer patients. Int J Oncol 2005; 27:870-81; PMID:15982410; http://dx.doi.org/10.1016/S1013-0361(05)00594-5

el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Deﬁnition of a consensus binding site for p53. Nat Genet 1992; 1:45-9; PMID:1301998; http://dx.doi.org/10.1038/ng0942-45

Berglund H, Pawitan Y, Kato S, Ishioka C, Soussi T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 2008; 7:699-708; PMID:18277095; http://dx.doi.org/10.4161/cbt.7.5.5712

Tomimori Y, Kato H, Kurata S, Okuyama T, Kamiyama R, Ikawa Y. Evolutionarily conserved expression pattern and trans-regulating activity of Xenopus p51/p63. Biochem Biophys Res Commun 2004; 313:230-6; PMID:14684151; http://dx.doi.org/10.1016/j.bbrc.2003.11.113

Ma Y, Ren Y, Han EQ, Li H, Chen D, Jacobs JJ, Gittelis S, O’Keefe RJ, Konttinen YT, Yin G, et al. Inhibition of the Wnt-beta-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy. Biochem Biophys Res Commun 2013; 431:274-9; PMID:23291185; http://dx.doi.org/10.1016/j.bbrc.2012.12.118

Austinv M, Dunsch R, Wittke K, Tannapfel A, Gebhardt R, Gaunitz F. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer 2008; 7:21; PMID:18282277; http://dx.doi.org/10.1186/1476-4598-7-21

Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistanian SK. Epigenetic reprogramming by adenovirus e1a. Science 2008; 321:1086-8; PMID:18719284; http://dx.doi.org/10.1126/science.1155546

Nishita M, Hashimoto MK, Ogata S, Laurent MN, Ueno N, Shibuuya H, Cho K. Interaction between Wnt and TGF-ß[alpha] signaling pathways during formation of Spemann’s organizer. Nature 2000; 403:781-5.

Nguyen H, Merrill BJ, Polak L, Nikolova M, Rendl M, Shaver TM, Pasolli HA, Fuchs E. Tcf3 and Tcf4 are essential for long-term homeostasis of skin epithelia. Nat Genet 2009; 41:1068-75; PMID:19718027; http://dx.doi.org/10.1038/ng.431

Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, et al. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. Mol Cell Biol 2008; 28:2732-44; PMID:18268006; http://dx.doi.org/10.1128/MCB.02175-07

Bottomly D, Kyler SL, McWeeny SK. Yochum GS. Identification of ß-catenin binding regions in colon cancer cells using ChIP-Seq. Nucl Acids Res 2010; 38:5735-45; PMID:20460455; http://dx.doi.org/10.1093/nar/gkq363

Cadigan KM, Waterman ML. TCF/LEFs and Wnt Signaling in the Nucleus. Cold Spring Harbor Perspect Biol 2012; 4:a007906; PMID:23024173

Ruptier C, De Gaspersis A, Ansieu S, Granjon A, Taniere P, Lafosse I, Shi H, Petitjean A, Taranchon Clermont E, Tribollet V, et al. TP63 P2 promoter functional analysis identiﬁes [beta]-catenin as a key regulator of [Delta]Np63 expression. Oncogene 2011; 30:4656-65; PMID:21643019; http://dx.doi.org/10.1038/onc.2011.171

Yamasita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrixin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 1998; 79:187-94; http://dx.doi.org/10.1002/(SICI)1097-0215(19980417)79:2<187::AID-IJC15>3.0.CO;2-7

Miyata Y, Iwata T, Ohba K, Kanda S, Nishikido M, Kanetake H. Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis. Clin Cancer Res 2006; 12:6998-7003; PMID:17145820; http://dx.doi.org/10.1158/1078-0432.CCR-06-1626

Jho E-H, Zhang T, Domon C, Joo C-K, Freund J-N, Costantini F. Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenesis. Proceedings Natl Acad Sci 2012; 109:11312-7; http://dx.doi.org/10.1073/pnas.1203015109

Fujimuro M, Hayward SD. The Latency-associated nuclear antigen of kaposi’s sarcoma-associated herpesvirus manipulates the activity of glycogen synthase kinase-3[beta]. J Virol 2003; 77:8019-30; PMID:12829841; http://dx.doi.org/10.1128/JVI.77.14.8019-8030.2003